Title: Clinical Effect of Adefovir Dipivoxil in Treating Chronic Hepatitis B and the P Gene of Hepatitis B Virus Mutation Analysis
Abstract: Objective To explore the effects of adefovir dipivoxil(ADV) in treating chronic hepatitis B,and virus drug-resistant mutation.Methods Among 89 patients with chronic hepatitis B,66 cases were lamivudine-resistant mutation patients(group A),receiving adefovir dipivoxil combined with lamivudine(LAM) therapy,and 23 cases were newly diagnosed patients(group B),receiving adefovir monotherapy.There were no differences in the baseline characteristics between group A and B.Patients were analyzed with HBV DNA,ALT,HBeAg,and the mutations in the P gene of hepatitis B virus(HBV) were detected medication for weeks 48~144.Results At week 12,24 and 48,Serum HBV DNA negative rate was 39.4%,54.5%and75.8%in group A,0%,13.0%and 47.8%in group B.Virological response was higher in the group A than group B(P0.05).At week 12 and 24,ALT normalization rate was 40.9%and 59.1%in group A,0% and 21.7%in group B.Biochemical response was higher in the group A than group B(P0.05).At 48 week,no significant difference was found in Serum HBeAg negative rate and ALT normalization rate between group A and B(P0.05). Medication for48,96 and 144 weeks,the virus mutation rates was 0%,3.4%and 5.6%.In genotype B and C,the virus mutation rates were 8.6%vs10.5%,which had no statistic difference(P0.05).In group A and B,the virus mutation rates were 9.1%vs 8.7%,which had no statistic difference(P0.05).Conclusion Adefovir dipivoxil is efficacious for chronic hepatitis B,and lower rate of drug-resistant mutation,and the inhibitory effect for lamivudine-resistant mutants is stronger than HBV wild strain.ADV combined with LAM therapy lamivudine resistance can improve the antiviral efficacy, and reduce the incidence of drug-resistance mutations.
Publication Year: 2011
Publication Date: 2011-01-01
Language: en
Type: article
Access and Citation
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot